ArticleCureus2025
Effectiveness of Multisymptom Support for Better Relief and Alleviation of Common Effects in Perimenopause (EMBRACE PERIMENOPAUSE).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMenopause affects 1.5 million women annually, with perimenopause lasting 2-8 years and causing symptoms like hot flashes, sleep disturbances, mood changes, and joint pain. While hormone replacement therapy (HRT) is effective, safety concerns limit its use, leading many women to seek nonhormonal alternatives. Nutraceuticals such as ashwagandha, vitex, and black cohosh offer potential benefits, with 80% of women using supplements. This study evaluates the efficacy and safety of Arth perimenopause multisymptom capsules, providing evidence for nutraceuticals as an alternative to HRT. METHODOLOGY: The Effectiveness of Multisymptom Support for Better Relief and Alleviation of Common Effects in Perimenopause (EMBRACE PERIMENOPAUSE) study was a prospective, observational trial conducted at Redkar Hospital and Research Center, Goa. Thirty perimenopausal women aged 40-48 years with irregular menstrual cycles and at least two menopausal symptoms received one Arth capsule daily for 60 days. Using standardized case report forms, data were collected at screening, baseline, and days 7, 15, 30, and 60. Primary outcomes included changes in menopausal symptoms (Menopause Rating Scale (MRS)), reduction in daily hot flashes, and improvement in breast tenderness. Secondary outcomes assessed the quality of life (QoL), changes in hair and skin texture, patient and physician global assessments, and intervention tolerability. Statistical analyses included Chi-square tests and analysis of variance (ANOVA) (p < 0.05).
resultsAt baseline, 100% of patients reported hot flashes, followed by irritability (90%) and night sweating (83%). The mean MRS score decreased from 39 at baseline to 2.74 by day 60 (-92.97%, p < 0.01). By day 60, 93% of patients achieved complete resolution of hot flashes, 88% for sweating, 91% for anxiety, and 90% for depressive mood (p < 0.05). Overall, treatment significantly improved menopausal symptoms, QoL, and patient satisfaction.
conclusionArth Perimenopause Multisymptom Support capsules demonstrated significant efficacy in alleviating perimenopausal symptoms while improving QoL. This nonhormonal, well-tolerated nutraceutical represents a promising alternative for managing perimenopause-related discomfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.